Abstract
The ubiquitin-proteasome proteolytic pathway plays a major role in selective protein degradation and regulates various cellular events including cell cycle progression, transcription, DNA repair, signal transduction, and immune response. Ubiquitin, a highly conserved small protein in eukaryotes, attaches to a target protein prior to degradation. The polyubiquitin chain tagged to the target protein is recognized by the 26S proteasome, a high-molecular-mass protease subunit complex, and the protein portion is degraded by the 26S proteasome. The potential of specific proteasome inhibitors, which act as anti-cancer agents, is now under intensive investigation, and bortezomib (PS-341), a proteasome inhibitor, has been recently approved by FDA for multiple myeloma treatment. Since ubiquitination of proteins requires the sequential action of three enzymes, ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin-protein ligase (E3), and polyubiquitination is a prerequisite for proteasome-mediated protein degradation, inhibitors of E1, E2, and E3 are reasonably thought to be drug candidates for treatment of diseases related to ubiquitination. Recently, various compounds inhibiting the ubiquitin-proteasome pathway have been isolated from natural resources. We also succeeded in isolating inhibitors against the proteasome and E1 enzyme from marine natural resources. In this review, we summarize the structures and biological activities of natural products that inhibit the ubiquitinproteasome proteolytic pathway.
Keywords: Natural product, ubiquitin-proteasome proteolytic pathway, ubiquitin, ubiquitination, ubiquitin-activating enzyme, ubiquitin-conjugating enzyme, ubiquitin-protein ligase, proteasome
Current Medicinal Chemistry
Title: Natural Products Inhibiting the Ubiquitin-Proteasome Proteolytic Pathway, A Target for Drug Development
Volume: 13 Issue: 7
Author(s): Sachiko Tsukamoto and Hideyoshi Yokosawa
Affiliation:
Keywords: Natural product, ubiquitin-proteasome proteolytic pathway, ubiquitin, ubiquitination, ubiquitin-activating enzyme, ubiquitin-conjugating enzyme, ubiquitin-protein ligase, proteasome
Abstract: The ubiquitin-proteasome proteolytic pathway plays a major role in selective protein degradation and regulates various cellular events including cell cycle progression, transcription, DNA repair, signal transduction, and immune response. Ubiquitin, a highly conserved small protein in eukaryotes, attaches to a target protein prior to degradation. The polyubiquitin chain tagged to the target protein is recognized by the 26S proteasome, a high-molecular-mass protease subunit complex, and the protein portion is degraded by the 26S proteasome. The potential of specific proteasome inhibitors, which act as anti-cancer agents, is now under intensive investigation, and bortezomib (PS-341), a proteasome inhibitor, has been recently approved by FDA for multiple myeloma treatment. Since ubiquitination of proteins requires the sequential action of three enzymes, ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin-protein ligase (E3), and polyubiquitination is a prerequisite for proteasome-mediated protein degradation, inhibitors of E1, E2, and E3 are reasonably thought to be drug candidates for treatment of diseases related to ubiquitination. Recently, various compounds inhibiting the ubiquitin-proteasome pathway have been isolated from natural resources. We also succeeded in isolating inhibitors against the proteasome and E1 enzyme from marine natural resources. In this review, we summarize the structures and biological activities of natural products that inhibit the ubiquitinproteasome proteolytic pathway.
Export Options
About this article
Cite this article as:
Tsukamoto Sachiko and Yokosawa Hideyoshi, Natural Products Inhibiting the Ubiquitin-Proteasome Proteolytic Pathway, A Target for Drug Development, Current Medicinal Chemistry 2006; 13 (7) . https://dx.doi.org/10.2174/092986706776055571
DOI https://dx.doi.org/10.2174/092986706776055571 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetically Modified Viruses Vaccines by Design
Current Pharmaceutical Biotechnology Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Investigations of Malignant Mesothelioma
Current Respiratory Medicine Reviews Effects of Agaricus Blazei Extract Plus Lactoferrin or Lactoferrin Alone on Tumor Growth and UFT-Induced Adverse Reactions in Sarcoma 180- or Highly Metastatic Osteosarcoma LM8-Bearing Mice
The Natural Products Journal KRAS: A Promising Therapeutic Target for Cancer Treatment
Current Topics in Medicinal Chemistry The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Novel Concepts in the Development of Platinum Antitumor Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy
Current Medicinal Chemistry Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design Integrins: Regulators of Tissue Function and Cancer Progression
Current Pharmaceutical Design New Strategies in the Chemotherapy of Leukemia: Eradicating Cancer Stem Cells in Chronic Myeloid Leukemia
Current Cancer Drug Targets Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Molecular and Biochemical Pathways Encompassing Diabetes Mellitus and Dementia
CNS & Neurological Disorders - Drug Targets Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets Bridge Between Neuroimmunity and Traumatic Brain Injury
Current Pharmaceutical Design Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Mutagenic Approaches to Modifying Gap Junction Phenotype
Current Drug Targets Effect of Liposomes with Different Double Arms Polyethyleneglycol on Hepatic Metastasis Model Mice and Evaluation Using a Fluorescent Imaging Device
Current Drug Delivery